LOPP化疗作为犬T细胞淋巴瘤的一线治疗方法。
LOPP chemotherapy as a first-line treatment for dogs with T-cell lymphoma.
作者信息
Brown P M, Tzannes S, Nguyen S, White J, Langova V
机构信息
Department of Oncology, Small Animal Specialist Hospital (SASH), North Ryde, Australia.
出版信息
Vet Comp Oncol. 2018 Mar;16(1):108-113. doi: 10.1111/vco.12318. Epub 2017 May 16.
BACKGROUND
The aim of this study was to describe the use of a lomustine (CCNU), vincristine, procarbazine and prednisolone (LOPP) protocol used for treatment of chemotherapy naive T-cell lymphoma patients and to describe the response rate, toxicity and disease-free interval compared historically to CHOP chemotherapy.
MATERIALS AND METHODS
Retrospective case study of 31 dogs with naïve T-cell lymphoma treated with a lomustine (CCNU), vincristine, procarbazine and prednisolone (LOPP) protocol.
RESULTS
Thirty-one dogs with T cell lymphoma were treated. The overall response rate was 97%. Of the 30 dogs that had a response to LOPP chemotherapy, the median disease free interval was 176 days (range 0-1745 days). The median overall survival time for this study group was 323 days (range 51-1758 days). All deaths in this study were attributable to lymphoma.
CONCLUSION
LOPP chemotherapy for T cell lymphoma is well tolerated with a low toxicity profile and an excellent overall response rate. This protocol showed minimal toxicity and comparable disease free interval and survival times for canine high grade T cell lymphoma treated with CHOP.
背景
本研究的目的是描述用于治疗初治T细胞淋巴瘤患者的洛莫司汀（CCNU）、长春新碱、丙卡巴肼和泼尼松龙（LOPP）方案的使用情况，并与CHOP化疗进行历史对照，描述缓解率、毒性和无病间期。
材料与方法
对31例初治T细胞淋巴瘤犬采用洛莫司汀（CCNU）、长春新碱、丙卡巴肼和泼尼松龙（LOPP）方案进行回顾性病例研究。
结果
31只患有T细胞淋巴瘤的犬接受了治疗。总缓解率为97%。在对LOPP化疗有反应的30只犬中，无病间期的中位数为176天（范围0-1745天）。该研究组的总生存时间中位数为323天（范围51-1758天）。本研究中的所有死亡均归因于淋巴瘤。
结论
用于T细胞淋巴瘤的LOPP化疗耐受性良好，毒性较低，总体缓解率极佳。该方案显示出最低的毒性，并且对于接受CHOP治疗的犬高级别T细胞淋巴瘤，其无病间期和生存时间相当。
Zotero 插件